Igm Biosciences
(NASDAQ) IGMS
This security has been delisted. This page is retained for historical reference.
IGMS News
![This_Biotech_Skyrocketed_84__in_2_Days,_But_Is_It_Warranted[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F605699%2Fthis_biotech_skyrocketed_84__in_2_days_but_is_it_warranted1.jpg&w=3840&op=resize)
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowIGMS Financials
Key Financial Metrics (TTM)
Gross Margin
98%
Operating Margin
25%
Net Income Margin
6%
Return on Equity
16%
Return on Capital
36%
Return on Assets
8%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$6.43M
Operating Income
$208.58M
EBITDA
$199.47M
Operating Cash Flow
$153.00M
Capital Expenditure
$5.85M
Free Cash Flow
$158.85M
Cash & ST Invst.
$183.79M
Total Debt
$45.19M
Igm Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$143.62M
+11353.2%
Gross Profit
$143.18M
+14110.0%
Gross Margin
99.69%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
149
N/A
Net Income
$97.58M
+303.7%
EBITDA
$98.02M
+299.7%
Quarterly Fundamentals
Net Cash
$104.31M
-52.0%
Accounts Receivable
$500.00K
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$0.00
-100.0%
Return on Assets
7.52%
N/A
Return on Invested Capital
36.20%
N/A
Free Cash Flow
$50.79M
-31.6%
Operating Cash Flow
$50.79M
-35.9%